Login
$MGTX
$8.74 -$0.44 (4.79%) Live

Company Executives

Officer Age In this role Joined 2025 pay Source
Alexandria Forbes Also a director
President and Chief Executive Officer and Director
61 Since 2015
11 years
Not stated $8,330,006
Richard Giroux
Chief Operating Officer and Chief Financial Officer
53 Not stated Not stated $8,148,500
Robert K. Zeldin
Chief Medical Officer
63 Not stated Not stated $1,616,123
Robert J. Wollin
General Counsel and Secretary
50 Not stated 2019 Not reported
Penny Renee Fleck
CHIEF DEVELOPMENT OFFICER
Title from the Form 4 dated May 13, 2026
Not stated Not stated Not stated Not reported
Stuart Naylor
CHIEF SCI OFCR, OPHTHALMOLOGY
Title from the Form 4 dated Oct 6, 2026
63 Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 30, 2026 · updated by the 8-K of Sep 23, 2026

Directors
8
serving now
Independent
5 of 7
stated in the proxy; 1 not stated
Average tenure
9.1 years
from year joined
CEO also chairs the board
No
Keith R. Harris, Ph.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Keith R. Harris, Ph.D.
73 2015
11 years
Independent None stated Global Connectivity PLC $674,250
Alexandria Forbes, Ph.D.
61 2015
11 years
Not independent None stated None stated Paid as CEO
Ellen Hukkelhoven, Ph.D.
39 2017
9 years
Not independent None stated Freenome Holdings, Inc., Partner Therapeutics, Inc. $296,550
Nicole Seligman
69 2019
7 years
Independent None stated Intuitive Machines, Inc., OpenAI, Praetorian Acquisition Corp. $406,050
Debra Yu, M.D.
61 2022
4 years
Independent None stated JW (Cayman) Therapeutics Co. Ltd. $389,050
Thomas E. Shenk, Ph.D.
79 2015
11 years
Independent None stated None stated $398,550
Lord Mendoza
66 2015
11 years
Independent None stated None stated $396,550
Alan M. Sebulsky Joined Sep 23, 2026
- - -
Science and Technology Committee
- -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

Directors and executive officers
directors and executive officers
Amount not stated

Indemnification agreements with each director and executive officer

Perceptive Credit Holdings
affiliate of Perceptive, a beneficial owner of more than 5% of our ordinary shares
$75.0 million
2022

Senior secured financing (Notes Purchase Agreement) with initial $75.0 million notes issuance

With Company as borrower Open in proxy
Perceptive Master Fund
$18,193,000

Company repurchased 2,300,000 ordinary shares under a share purchase agreement

Sanofi
beneficial holder of more than 5% of our ordinary shares at that time
Amount not stated
2024

Purchased 7,500,000 ordinary shares in August 2024 public offering

Perceptive Advisor
beneficial holder of more than 5% of our ordinary shares at that time
Amount not stated
2024

Purchased 1,250,000 ordinary shares in August 2024 public offering

Prosight Management, LP
beneficial holder of more than 5% of our ordinary shares at that time
Amount not stated
2024

Purchased 375,000 ordinary shares in August 2024 public offering

Rubric Capital
beneficial holder of more than 5% of our ordinary shares
Amount not stated
2026

Purchased 1,600,000 ordinary shares in April 2026 public offering

Perceptive Advisor
beneficial holder of more than 5% of our ordinary shares
Amount not stated
2026

Purchased 555,555 ordinary shares in April 2026 public offering

Adage
beneficial holder of more than 5% of our ordinary shares
Amount not stated
2026

Purchased 400,000 ordinary shares in April 2026 public offering

Hologen Limited
$200 million
2025

Strategic collaboration with upfront cash payment to the Company and related framework agreements

Dr. Forbes and Mr. Giroux
received a nominal equity interest in Hologen and are members of Hologen's Scientific Advisory Board and Advisory Board, respectively
Amount not stated
2025

Nominal equity interest in Hologen held by Dr. Forbes and Mr. Giroux, who serve on Hologen advisory boards

With Hologen Limited Open in proxy
Johnson & Johnson Innovation – JJDC, Inc.
owner of Seller and owns more than 5% of our outstanding shares
$25,000,000
2026

Asset Purchase Agreement for RPGR gene therapy product and related assets with upfront cash purchase price to Seller

With Janssen Pharmaceuticals, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support